Navigation Links
SafeCode Drug Technologies Initiating Activities to Commercialize its Recent Newly Acquired Technology of the Pain-Free Injection
Date:3/21/2013

JERUSALEM, March 21, 2013 /PRNewswire/ --

SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of voice activated drug safety application announced today that the company is actively initiating a business development plan to commercialize its newly acquired technology.

During the first stage of the business development plan, SafeCode intends to initiate a formal search for market-tested executives to help the company's management team and to raise additional funds to reach its commercialization objectives.

The company recently reported that SafeCode Drug Technologies acquired Quickool and EZJect technology from Sindolor Medical Ltd., an Israel-based medical technologies development company.  The breakthrough Quickool technology enabling individuals to self-administer pain free injections.

The technologies enable individuals to safely and painlessly administer injections or blood lancing, by quickly cooling the site of the injection immediately prior to the piercing of the skin.  The technology is particularly useful for patients with diabetes who need to test blood-sugar levels or inject themselves regularly with insulin.  

Sindolor had previously been in involved in advanced negotiations with a major pharmaceutical company to fully commercialize the painless injection technology.

"The company is extremely optimistic that we can bring our newly acquired pain reduction technologies to market, in addition to the market-tested life-saving technologies that SafeCode already offers," said Joel Klopfer , Chief Executive Officer of SafeCode Drug Technologies.  "We are excited by the opportunities this technology presents to our shareholders, and we intend to keep providing updates on our business development activities."

About SafeCode Drug Technologies

SafeCode Drug Technologies is the developer of patent-pending technologies based on voice recognition for drug safety application.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:
Joel Klopfer
Joel.Klofer1@gmail.com
+9722-5021322



'/>"/>
SOURCE Safecode Drug Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
2. SafeCode Drug Technologies Corp. in Negotiations With Manufacturers to Develop Prototype
3. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
4. SafeCode Drug Technologies Corporation Identifies the Technology Group to Commence and Develop the Worlds First Prototype for its Next Generation Application for Drug Safety Administration
5. SafeCode Drug Technologies Corp Signs an Agreement With INTOVISION PRODUCT DEVELOPMENT & DESIGN (An Israeli Product Development Co) to Manufacturers the Worlds First Voice Recognition Drug Safety Application Prototype
6. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
7. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
11. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
(Date:6/23/2016)... , June 23, 2016  The National Pharmaceutical ... joined the health policy research organization as its ... , MD, senior vice president and chief scientific ... representative on the NPC Board of Directors. ... that Mallinckrodt has joined us in support of ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):